Enanta Pharmaceuticals (ENTA) Accumulated Depreciation & Amortization (2012 - 2025)

Enanta Pharmaceuticals (ENTA) has 14 years of Accumulated Depreciation & Amortization data on file, last reported at $23.8 million in Q3 2025.

• For the quarter ending Q3 2025, Accumulated Depreciation & Amortization fell 4.96% year-over-year to $23.8 million; the trailing twelve-month figure through Sep 2025 stood at $23.8 million (down 4.96% YoY), and the FY2025 full-year result was $23.8 million, down 4.96% from the prior year.
• Accumulated Depreciation & Amortization for Q3 2025 stood at $23.8 million, up from $22.5 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $25.2 million in Q2 2024 and bottomed at $18.9 million in Q3 2021.
• The 5-year median for Accumulated Depreciation & Amortization is $22.5 million (2025), against an average of $22.5 million.
• The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization advanced 20.75%; it then dropped 10.67% in 2025.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $18.9 million in 2021, then climbed by 15.49% to $21.9 million in 2022, then advanced by 8.63% to $23.7 million in 2023, then slipped by 15.23% to $20.1 million in 2024, then grew by 18.26% to $23.8 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $23.8 million (Q3 2025), $22.5 million (Q2 2025), and $21.3 million (Q1 2025), per Business Quant data.

Peer Comparison